1. Endovascular embolization in treatment of brain arteriovenous malformation combined with aneurysms
Chinese Journal of Interventional Imaging and Therapy 2019;16(1):8-11
Objective: To investigate the value of endovascular embolization in treatment of brain arteriovenous malformation (BAVM) combined with aneurysms. Methods Totally 46 patients with brain arteriovenous malformation combined with aneurysm were enrolled. Patients with Redekop type Ⅱa and III BAVM were embolized with Onyx combined with coils (group A), while with Redekop type and Ⅱb BAVM were embolized with Onyx combined with coil or only Onyx (group B). Then the effect of embolization was evaluated using Glasgow outcome scale (GOS) score. Cerebral angiography was reviewed 3 months after treatment to observe whether the lesions recurred or not. Results: The postoperative GOS of group A was 4.70±0.47. In group B, GOS of patients embolized with Onyx combined with coil (4.75±0.45) was significantly higher than those with only Onyx (4.33±0.49; t=2.159, P=0.042). One patient died, 45 patients underwent cerebral angiography after 3 months, and no recurrence was found. Conclusion :Endovascular embolization is effective for brain arteriovenous malformation with aneurysms, and embolization using Onyx combined with coil is better than only Onyx embolization.
2.Transarterial chemoembolization by using CalliSpheres drug-eluting beads combined with 8Spheres microsphere for the treatment of advanced hepatocellular carcinoma: study on its short-term efficacy and safety
Jiangping CUN ; Yongneng JIANG ; Xuan ZONG ; Cheng WAN ; Hongjie FAN ; Shunran CAI
Journal of Interventional Radiology 2019;28(3):237-241
Objective To investigate the clinical short-term efficacy and safety of transarterial chemoembolization (TACE) by using CalliSpheres drug-eluting beads combined with blank microspheres (8 Spheres) in treating advanced hepatocellular carcinoma (HCC) . Methods The clinical data of 98 HCC patients, who were treated at authors′ hospital during the period from July 2016 to November 2017, were retrospectively analyzed. The patients were divided into DEB-TACE group (receiving TACE by using CalliSpheres drug-eluting beads combined with 8 Spheres embolic microspheres, n =50) and cTACE group (receiving TACE by using opium poppy ethyl iodized oil together with 8 Spheres embolic microspheres, n =48) . The disease remission rate, control rate and incidence of complications as well as preoperative and 3-day postoperative hepatic function indexes were collected, and the results were compared between the two groups. Results No statistically significant differences in baseline data existed between the two groups (P>0.05) . Both the 3-month and the 6-month disease remission rates in DEB-TACE group were remarkably higher than those in cTACE group (P<0.05), besides, the 6-month disease progression rate and the incidence of elevated serum AFP in DEB-TACE group were lower than those in cTACE group, the short-term efficacy of DEB-TACE group was better than that of cTACE group (P<0.05) . Three days after treatment, the levels of ALT and AST in cTACE group were strikingly higher than those in DEB-TACE group (P<0.05) . No serious adverse reactions occurred in both groups. Conclusion In treating advanced HCC with TACE, the short-term efficacy and safety of CalliSpheres drug-eluting beads combined with 8 Spheres embolic microspheres are superior to those of opium poppy ethyl iodized oil together with 8 Spheres embolic microspheres.